Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis

Company Overview

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States. In May 2022, the U.S. Food and Drug Administration approved Phathom’s vonoprazan‐based triple therapy regimen, marketed under the brand name Voquezna™ Triple Pak, for first‐line treatment of H. pylori infection. Phathom has also pursued additional filings for vonoprazan in erosive esophagitis and other acid‐related disorders. Beyond vonoprazan, Phathom’s pipeline includes investigational compounds in earlier stages of clinical development targeting gastroparesis and functional dyspepsia.

Founded in 2018 and headquartered in Redwood City, California, Phathom Pharmaceuticals completed its initial public offering in October 2020 and trades on the NASDAQ under the ticker symbol PHAT. The company was established to build a specialty GI franchise by acquiring and advancing differentiated assets in gastroenterology. Phathom operates a lean organizational structure, collaborating with clinical investigators and strategic partners to conduct trials and prepare regulatory submissions.

Under the leadership of President and Chief Executive Officer Dan Lynch, Phathom continues to expand its commercial infrastructure to support product launches and market access efforts in the United States. The company is also exploring partnerships and licensing arrangements to extend its reach into international markets. With a focus on high‐impact GI indications and a growing portfolio of late-stage programs, Phathom aims to become a leader in therapies that address chronic and serious gastrointestinal diseases.

Key Stats

• Today's Range: $8.32 to $9.03
• 50-Day Range: $8.75 to $12.61
• 52-Week Range: $8.02 to $18.31
• Volume: 2.19 million shs
• Average Volume: 1.23 million shs
• Market Capitalization: $683.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.43
• Consensus Rating: Moderate Buy

Phathom Pharmaceuticals Stock Analysis - MarketRank™

Phathom Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 382nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Phathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Phathom Pharmaceuticals has a consensus price target of $23.43, representing about 177.3% upside from its current price of $8.45.

Amount of Analyst Coverage

Phathom Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($0.25) to $1.56 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Phathom Pharmaceuticals is -6.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Phathom Pharmaceuticals is -6.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.76% of the float of Phathom Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 9.

Change versus previous month

Short interest in Phathom Pharmaceuticals has recently increased by 1.07%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Phathom Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Phathom Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.06

News Sentiment

Phathom Pharmaceuticals has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

7 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.33% of the stock of Phathom Pharmaceuticals is held by insiders.

Percentage Held by Institutions

99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/26/2026
• Today: 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PHAT
• CIK: 1783183
• Web: www.phathompharma.com
• Phone: 877-742-8466
• Fax: N/A
• Employees: 110
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Phathom Pharmaceuticals: $23.43
• High Price Target: $28.00
• Low Price Target: $18.00
• Potential Upside/Downside: +177.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$221.25 million
• Net Margins: -41.34%
• Pretax Margin: -41.34%
• Return on Equity: N/A
• Return on Assets: -20.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.92
• Quick Ratio: 1.87

Sales & Book Value

• Annual Sales: $175.11 million
• Price / Sales: 3.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.14) per share
• Price / Book: -1.38

Miscellaneous

• Outstanding Shares: 80,900,000
• Free Float: 73,353,000
• Market Cap: $683.61 million
• Optionable: Optionable
• Beta: 0.51